Some results of the use of specific antiviral therapy in patients with a new coronavirus infection
- 作者: Gonchar I.V.1, Kharisov A.M.1, Chernikov A.L.1, Ershov A.V.2,3, Sukhoterin A.F.4
-
隶属关系:
- Branch No. 3 of the A.A.Vishnevsky 3rd Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
- The V.A.Negovsky Research Institute of General Resuscitation of the Federal Scientific and Clinical Center for Resuscitation and Rehabilitation
- The I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
- Health-resort «Zvenigorodsky» of the health-resort complex «Podmoskovye» of the Ministry of Defense of the Russian Federation
- 期: 卷 343, 编号 7 (2022)
- 页面: 33-36
- 栏目: Treatment and prophylactic issues
- URL: https://journals.eco-vector.com/0026-9050/article/view/629921
- DOI: https://doi.org/10.52424/00269050_2022_343_7_33
- ID: 629921
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
The study included 885 patients. According to the results on the second day of hospitalization, all patients were divided into two groups: patients with a negative PCR test result in the presence of clinical signs of coronavirus infection (group I, n=410) and patients with a positive PCR test result (group II, n=475). Initially, there were no differences between the groups in terms of severity, main clinical manifestations and the course of the disease at the time of hospitalization, during treatment, and at the time of discharge. The treatment success rate was 83.9%, relative to mortality – 96.6%. Based on the data received, there were no statistically significant differences in the results of treatment depending on the prescription of various types of specific antiviral therapy in patients with a new coronavirus infection regarding mortality and the development of complications.
作者简介
I. Gonchar
Branch No. 3 of the A.A.Vishnevsky 3rd Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
编辑信件的主要联系方式.
Email: nachmed-60@mail.ru
подполковник медицинской службы
俄罗斯联邦, Odintsovo, Moscow RegionA. Kharisov
Branch No. 3 of the A.A.Vishnevsky 3rd Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
Email: nachmed-60@mail.ru
кандидат медицинских наук, полковник медицинской службы
俄罗斯联邦, Odintsovo, Moscow RegionA. Chernikov
Branch No. 3 of the A.A.Vishnevsky 3rd Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
Email: nachmed-60@mail.ru
капитан
俄罗斯联邦, Odintsovo, Moscow RegionA. Ershov
The V.A.Negovsky Research Institute of General Resuscitation of the Federal Scientific and Clinical Center for Resuscitation and Rehabilitation; The I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Email: salavatprof@mail.ru
доктор медицинских наук
俄罗斯联邦, Moscow; MoscowA. Sukhoterin
Health-resort «Zvenigorodsky» of the health-resort complex «Podmoskovye» of the Ministry of Defense of the Russian Federation
Email: salavatprof@mail.ru
кандидат медицинских наук, подполковник медицинской службы запаса
俄罗斯联邦, Zvenigorod, Moscow region参考
- Воробьева Ю.Д., Дюкова Г.М. Астенический синдром в контексте пандемии COVID-19 // Мед. алфавит. – 2020. – № 33. – С. 26–34. DOI.org/10.33667/2078-5631-2020-33-26-34
- Громов А.А., Кручинина М.В., Рабко А.В. Коронавирусная болезнь COVID-19: неиспользованные возможности терапии // Рус. мед. журн. – 2020. – № 9. – С. 2–6.
- Зайцев А.А., Голухова Е.З., Мамалыга М.Л., Чернов С.А., Рыбка М.М., Крюков Е.В. и др. Эффективность пульс-терапии метилпреднизолоном у пациентов с COVID-19 // Клин. микробиология и антимикроб. химиотерапия. – 2020. – Т. 22, № 2. – С. 88–91.
- Зайцев А.А., Чернов С.А., Стец В.В., Паценко М.Б., Кудряшов О.И., Чернецов В.А., Крюков Е.В. Алгоритмы ведения пациентов с новой коронавирусной инфекцией COVID-19 в стационаре. Метод. реком. // Consilium Medicum. – 2020. – Т. 22, № 11. – С. 91–97.
- Руженцова Т.А. Возможности этиотропной терапии коронавирусной инфекции, вызванной SARS-COV-2, у амбулаторных пациентов // Мед. оппонент. – 2020. – № 1 (9). – С. 48–58. DOI.org/10.21055/preprints-3111729
- Туличев А.А., Марасанов Б.О., Авилкин И.С. и др. Опыт применения ингибитора JAK-киназ в сочетании с низкими дозами преднизолона в лечении тяжелой коронавирусной инфекции // Мед. альманах. – 2021. – № 1 (66). – С. 52–56.
- Чикина С.Ю., Бровко М.Ю., Роюк В.В., Авдеев С.Н. Нетипичное течение новой коронавирусной инфекции COVID-19 с поздним повышением уровня С-реактивного белка (клинические наблюдения) // Пульмонология. – 2020. – Т. 30, № 5. – С. 709–714. DOI.org/10.18093/0869-0189-2020-30-5-709-714
- Esakandari H., Nabi-Afjadi M., Fakkari-Afjadi J. et al. A comprehensive review of COVID-19 characteristics // Biol. Proced. Online. – 2020. – Vol. 22, N 19. doi: 10.1186/s12575-020- 00128-2
- Goldman J. D., Lye D. C.B., Hui D. S. et al. GS–US–540-5773 Investigators. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 // N. Engl. J. med. –2020. – Vol. 383, N 19. – Р. 1827–1837. DOI.org/10.1056/NEJMoa2015301
- Hossen M.S., Barek M.A., Jahan N. et al. A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges // SN Compr. Clin. Med. – 2020. – Р. 1–13. doi: 10.1007/s42399-020-00485-9
- Lopez-Jimenez F., Rohde L.E., Luna-Jimenez M.A. Problems and solutions in the interpretation of diagnostic tests // Rev. Invest. Clin. – 1998. – Vol. 50, N 1. – P. 65–72. PMID: 9608793
- Prakash A., Singh H., Kaur H. et al. Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients // Indian J. Pharmacol. – 2020. – Vol. 52, Iss. 5. – Р. 414–421. doi: 10.4103/ijp.ijp_998_20
- Udwadia Z.F., Singh P., Barkate H. et al. Efficacy and safety of favipiravir, an oral RNA–dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open–label, multicenter, phase 3 clinical trial // Int. J. Infect. Dis. – 2021. – N 103. – Р. 62–71. doi: 10.1016/j.ijid.2020.11.142
- Vabret N., Britton G. J., Gruber C. et al. Immunology of COVID-19: Current State of the Science // Immunity. – 2020. – Vol. 52, Iss. 6. – Р. 910–941. DOI.org/10.1016/j.immuni. 2020.05.002
- Wu L., O’Kane A.M., Peng H. et al. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management // Biochem. Pharmacol. – 2020. – Vol. 178. – Р. 114. DOI: 1 0.1016/j.bcp.2020.114114
- Yoshimoto F.K. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2 or n-COV19), the Cause of COVID-19 // Protein J. – 2020. – Vol. 39, Iss 3. – Р. 198–216. doi: 10.1007/s10930-020-09901-4
补充文件
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).